Comprehensive, easy-to-understand information about this condition
How we create this content →Documentation for primary biliary cholangitis 1 is limited due to its rarity and the absence of systematically collected clinical data. As the condition is not well characterized, fewer studies have been conducted, and the clinical features remain largely unknown. This situation can be frustrating for patients seeking information and support.
To navigate your care for primary biliary cholangitis 1, consider consulting a hepatologist who specializes in liver diseases, particularly those with experience in cholestatic liver disorders. While there are currently no specific patient organizations identified, you can explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for additional support and information. Participating in clinical trials may also provide access to cutting-edge treatments and contribute to the understanding of this condition.
There are currently 16 orphan drugs associated with primary biliary cholangitis 1, including two FDA-approved treatments: elafibranor and seladelpar. Additionally, several drugs are in development, such as budesonide and Golexanolone. There are also 5 active clinical trials exploring various treatment options. For more information on these trials, visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=primary%20biliary%20cholangitis%201.
Actionable guidance for navigating care for primary biliary cholangitis 1
To navigate your care for primary biliary cholangitis 1, consider consulting a hepatologist who specializes in liver diseases, particularly those with experience in cholestatic liver disorders. While there are currently no specific patient organizations identified, you can explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for additional support and information. Participating in clinical trials may also provide access to cutting-edge treatments and contribute to the understanding of this condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation for primary biliary cholangitis 1 is limited due to its rarity and the absence of systematically collected clinical data. As the condition is not well characterized, fewer studies have been conducted, and the clinical features remain largely unknown. This situation can be frustrating for patients seeking information and support.
To navigate your care for primary biliary cholangitis 1, consider consulting a hepatologist who specializes in liver diseases, particularly those with experience in cholestatic liver disorders. While there are currently no specific patient organizations identified, you can explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for additional support and information. Participating in clinical trials may also provide access to cutting-edge treatments and contribute to the understanding of this condition.
There are currently 16 orphan drugs associated with primary biliary cholangitis 1, including two FDA-approved treatments: elafibranor and seladelpar. Additionally, several drugs are in development, such as budesonide and Golexanolone. There are also 5 active clinical trials exploring various treatment options. For more information on these trials, visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=primary%20biliary%20cholangitis%201.
Actionable guidance for navigating care for primary biliary cholangitis 1
To navigate your care for primary biliary cholangitis 1, consider consulting a hepatologist who specializes in liver diseases, particularly those with experience in cholestatic liver disorders. While there are currently no specific patient organizations identified, you can explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for additional support and information. Participating in clinical trials may also provide access to cutting-edge treatments and contribute to the understanding of this condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation for primary biliary cholangitis 1 is limited due to its rarity and the absence of systematically collected clinical data. As the condition is not well characterized, fewer studies have been conducted, and the clinical features remain largely unknown. This situation can be frustrating for patients seeking information and support.
To navigate your care for primary biliary cholangitis 1, consider consulting a hepatologist who specializes in liver diseases, particularly those with experience in cholestatic liver disorders. While there are currently no specific patient organizations identified, you can explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for additional support and information. Participating in clinical trials may also provide access to cutting-edge treatments and contribute to the understanding of this condition.
There are currently 16 orphan drugs associated with primary biliary cholangitis 1, including two FDA-approved treatments: elafibranor and seladelpar. Additionally, several drugs are in development, such as budesonide and Golexanolone. There are also 5 active clinical trials exploring various treatment options. For more information on these trials, visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=primary%20biliary%20cholangitis%201.
Actionable guidance for navigating care for primary biliary cholangitis 1
To navigate your care for primary biliary cholangitis 1, consider consulting a hepatologist who specializes in liver diseases, particularly those with experience in cholestatic liver disorders. While there are currently no specific patient organizations identified, you can explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for additional support and information. Participating in clinical trials may also provide access to cutting-edge treatments and contribute to the understanding of this condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Inheritance patterns describe how genetic conditions are passed from parents to children.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.